Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Boehringer Ingelheim Pioneers Biopharmaceuticals Move to China

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
First international company using cell culture technology to produce biopharmaceuticals in China.

Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology.

The facility set up will include technical process development and cGMP manufacturing which will be ready for operations early 2016. Boehringer Ingelheim plans an investment of over 35 million EUR. The project will create up to 65 job opportunities with high qualification standards.

“Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high quality biopharmaceuticals in China”, stated Christian Boehringer, Chairman of the Shareholders Committee.”Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources.”

Lanzhong Wang, General Manager of the ZJ Base Company commented: “We are very pleased to start the partnership with a leading biopharmaceuticals company like Boehringer Ingelheim. Through the cooperation, we hope to bring here the know-how, technology and experience, all up to international standards. With a number of innovative medicines being developed by a cluster of middle to small-sized innovative companies in Zhangjiang, plus the government support, we plan to initiate the CMO manufacturing framework at this plant on a trial basis. This will provide an effective platform for middle and small-sized companies to industrialize their innovations. Thus, it will greatly prompt the development of China’s biopharmaceuticals manufacturing industry.”

Hubertus von Baumbach, member of the Board of Managing Directors, in charge of Finance, commented: “Since 1994 Boehringer Ingelheim is present in China and has established significant research, development, manufacturing and marketing activities. With our investments in these innovation-driven areas we strive to meet the needs of our customers. The move to invest in biopharmaceuticals is in line with China’s overall growth plan for the next five years. Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing, will form the five pillars driving our business in China.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Collaboration to Develop New Class of Medicines
Boehringer Ingelheim and University of Dundee collaborate to develop a new therapeutic modality that is able to degrade proteins playing a central role in disease processes.
Friday, July 15, 2016
Boehringer Ingelheim Acquires Pharmaxis’ Phase 1 Anti-inflammatory Drug Candidate
Company exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights.
Friday, May 22, 2015
Boehringer Ingelheim and Sanofi Enter into Alliance
Strategic contract manufacturing alliance to produce biopharmaceuticals.
Thursday, January 22, 2015
BI and Yale Collaborate to Investigate Immunotherapy Targets
Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas.
Wednesday, January 14, 2015
Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance
Significant portion of alliance opportunity will remain unchanged.
Friday, October 31, 2014
Boehringer Ingelheim Announces Growth for Financial Year 2012
Net sales rose by 11.5 percent to around €14.7 billion and sales of PRADAXA® exceeded €1 billion.
Tuesday, April 30, 2013
Boehringer Ingelheim Expands Capabilities in Biopharmaceutical Process Science
Invests approx. 17 million Euros in development and manufacturing capabilities.
Thursday, March 15, 2012
Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX Technology
Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC activity of antibodies.
Friday, August 19, 2011
Boehringer Ingelheim and Priaxon Collaborates to Research and Develop Novel Treatments for Cancer
Companies to advance mdm2/p53 inhibitors, which hold potential to address various tumor types.
Tuesday, January 19, 2010
FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
First once-daily steroid-free maintenance treatment that has been shown to reduce exacerbations for people with COPD.
Friday, December 18, 2009
Boehringer Ingelheim and Vitae Announce R&D Collaboration to Develop Treatments for Alzheimer’s Disease
Companies to advance beta-secretase inhibitors, which hold potential for slowing the progression of the neurodegenerative disease.
Tuesday, June 16, 2009
Boehringer Ingelheim and DeveloGen AG Announce an Asset Sale and Purchase Agreement
The collaboration agreement covers the field of diabetes, obesity, the metabolic syndrome, and insulin resistance associated disorders.
Monday, May 18, 2009
Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partners are utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by BI.
Wednesday, October 31, 2007
Boehringer Ingelheim Renews Global SRS License
BioWisdom SRS will be responsible for upgrading the Biberach (Germany) and Ridgefield (USA) sites to new versions of the software.
Monday, May 22, 2006
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!